Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-08-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于2024年半年度计提减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the impairment provision for the half-year period ending June 30, 2024. It details the reasons, scope, amounts, and accounting basis for the impairment provisions, including bad debt and inventory write-downs. The document includes specific financial figures and explanations of accounting policies applied. The document length is 3687 characters, which is relatively short but contains substantive financial data and analysis related to the half-year period. It is not a full interim report but a specific announcement about impairment provisions for the half-year. This type of document is best classified as a Regulatory Filing (RNS) because it is a specific announcement about accounting estimates and provisions rather than a comprehensive interim or annual financial report. It is not a report publication announcement since it contains detailed financial data and explanations, not just a notice of report availability.
2024-08-28 Chinese
关于完成工商变更登记的公告
Regulatory Filings Classification · 100% confidence The document is an announcement regarding the completion of a business registration change, specifically the change of the company's registered address and the filing of the updated Articles of Association. It includes details about the new business license and registration information. There is no financial data, no mention of financial results, no discussion of management changes beyond the address update, and no indication of a report being attached or published. This type of announcement is a regulatory update about company registration details, which fits best under the category of Regulatory Filings (RNS). The document length is short and focused solely on the registration change, confirming it is not a full report or financial filing.
2024-08-13 Chinese
赛隆药业2024年第二次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2024 second extraordinary shareholders' meeting of a company. It details the legality and validity of the meeting's call, attendance, and voting process, but does not contain financial statements or management discussion of financial results. It is not an annual or interim report, earnings release, or any financial report. It is also not a proxy solicitation or voting results announcement by itself, but a legal opinion on the meeting. The document length is 3735 characters, which is relatively short and focused on legal opinion. Therefore, it fits best under Regulatory Filings (RNS) as a legal compliance document related to corporate governance and shareholder meetings but not a direct governance report or voting results announcement. Confidence is high due to clear legal opinion nature and absence of financial data or voting result announcement format.
2024-08-06 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary shareholders' meeting of Sailong Pharmaceutical Group Co., Ltd. It details the meeting date, voting procedures, attendance, and voting results on proposals, including changes to the company registration address and amendments to the articles of association. It also includes a legal opinion confirming the legality of the meeting and voting process. The document is an official announcement of voting results from a shareholders' meeting, not the meeting materials themselves or a full report. The document length is short (1815 characters), consistent with a voting results announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-08-06 Chinese
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding unusual stock price fluctuations over a few trading days. It includes statements about the company's investigation into the cause, confirmation of no undisclosed material information, and a risk warning to investors. It explicitly states that the company will disclose its half-year report on a future date but does not contain any financial data or report itself. The document is short (1219 characters) and serves as a regulatory disclosure about stock price movement and information verification, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-08-04 Chinese
关于持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, timing, and conditions. The document includes legal and regulatory compliance statements and risk warnings related to the share reduction plan. There are no financial statements, earnings data, or management discussion of financial results. The document is a notification about a major shareholding change, specifically a planned reduction by a significant shareholder, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2568 characters, which is typical for such announcements and not a full report or regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2024-07-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.